secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2021-09-16T23:59:59+00:00
Accession:  0001193125-21-274670
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen to acquire Avitide for ~$150M in cash and stock, adding affinity chromatography capabilities
--------------------------------------------------------------------------------

- Total consideration ~$150M, consisting of $75M cash and $75M in Repligen common stock, plus three-year earnout.
- Avitide expected to contribute ~$10M revenue in 2022 and be accretive to adjusted EPS in 2023.
- Transaction strengthens Repligen's affinity ligand discovery platform for gene therapy and other modalities.
- Deal expected to close in Q3 2021; funded with cash on hand ($734M at June 30, 2021).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312521274670/0001193125-21-274670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312521274670/d217967d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-274670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer